biopharm, it is all about recognition.
We are leaving an era where it was only UTSW (Dr. Thorpe and Brekken Labs) and PPHM that where talking about PS-Targeting, then about Bavituximab with a lesser understood MOA and finally about the broadly applicable and quite unique upstream/global/systemic signalling features of Bavituximab after a better understood MOA.
Now we have Memorial Sloan Kettering (Wolchok), Rutger's (Birge), Moffit Cancer Center (Antonia), Wistar (Gabrilovich) and several other Key Opinion Leaders joining UTSW (Brekken Labs) and PPHM's own Scientist which are slowly but surely themselves becoming PS-Targeting Koryphäes.
The fact that also our clinical trials program is advanced and all signs point to consistent safety over all trials and extremely good results in PII NSCLC and Breast and that some good results in other ones, attracts attention. The market likes to avoid risk and two of the main risks of biotech are that clinical trials deliver bad or poor results and that the company is not able to sponsor the trial till approval.
But what I think will motivate Dog & Pony show organizers more is very possibly the Bavituximab application profile. I still try to find a precedent drug with an application profile like Bavituximab:
- Oncology (Bavituximab is NOT cancer specific, all solid cancers)
--> Chemo
--> Radio
--> Immuno
- Diagnostics
--> Digital Imaging - PNG????
--> Biomarkers ?
- Viral (
--> hepatitis C
--> Ebola and comparable
--> replacement of interferon in cocktails (auto-immune, influenza?).
- Inflammations
--> replacement anti-biotic who are at end of strength improvement
--> pre-post surgery and other PS damaging treatments
- Vaccines
- Blood Brain Barrier (Alzheimer, ...)
- Animal (Bird flue (chikkens), Creutzfeldt–Jakob(Cows), etc)
Bavituximab is for Pfizer the PERFECT vaccine additive and for GILD the perfect cornerstone molecule and for Merck, BMY, Roche and AstraZeneca (and possible others to come such as Novartis) the perfect Joker to win the anti-PD-1,PD-L1,PD-L2,CTLA-4, etc race to make the SOC and increase the responders footprint and reduce the side effects.
Peregrine Pharmaceuticals KNOWS THAT, because if we know it it would be unacceptable that they don't know it. And with the recent shift in dialogue, PS-Targeting is now linked to Bavituximab and with the recognitions that this is upstream signalling Wall Street will slowly but sure start to see the HUGE potential value too. We control all IP and related pipelines UNENCUBERED.
I said it before: WE ARE OPERATING UNDER THE FALSE IMPRESSION THAT PPHM IS KNOWN AND THAT THE MARKETS KNOW ABOUT BAVITUXIMAB!!!
Nothing is further from the trued. We have that impression because we are better informed on this board then all those that follow official channels. We have a WEALTH of research and D&D that is done here, posted here, sometimes MONTHS before PPHM discloses it because our board posters surf all conventions, paper newsletters, gov's (SEC, FDA, ...), EDGAR, PACER, magazines and we visit annuals, listen and analyse quarterly's CC/Q&A's and we see reports from some analysts amongst whom some like Piper Jaffrey's.
But if you would walk through Wall Street and ask by-passers if they ever heard of PPHM you'd be surprised. We aren't even allowed on CNBC covering yet, unless eventful news, because our market capital is below 500Mil$, we cannot be in portfolio's of many IIs and Funds because they have 2$ or 5$ thresholds for the PPS before investing, we cannot be in other portfolios because we have an appeal for authorisation to start a CA pending, we had a going concern in 2012 and a sabotage of a clinical trial that clouded our PII results, until salvaged and solved, that will have kept many people away and, possibly most importantly, WE NEVER CAUGHT the ear or eye of the broad wide public with some news that interests ALL.
But with Bavituximab very probably being a KEY COMPONENT in the cocktails that are slowly but sure moving in the direction of the CURE (as in CURE) of cancer all this is going to change.
And your observation bio, that CEO King may now suddenly speak/present in a small select club of 16 companies is the FIRST leg in that development. Dog & Pony maybe, but we are moving to the price dogs category now. Not long any more or every dog breeder will want ... well poor King :)
News 
Market Data 
Discover 
